We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+14.09%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$1.54B
AUM Growth
+$254M
Cap. Flow
+$211M
Cap. Flow %
13.67%
Top 10 Hldgs %
62.61%
Holding
55
New
12
Increased
18
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$51.4M
2
TGTX icon
TG Therapeutics
TGTX
+$28.8M
3
BMY icon
Bristol-Myers Squibb
BMY
+$28.5M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$26.8M
5
AZN icon
AstraZeneca
AZN
+$25.3M

Top Sells

Rank Stock Value
1
KITE
Kite Pharma, Inc.
KITE
+$89.4M
2
TSRO
TESARO, Inc.
TSRO
+$25.2M
3
PCRX icon
Pacira BioSciences
PCRX
+$18.3M
4
MDCO
Medicines Co
MDCO
+$13.1M
5
DBVT
DBV Technologies
DBVT
+$8.22M

Sector Composition

Rank Sector Weight
1 Healthcare 76.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
51
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$784B
– –
-250,000
Closed -$469K
TPST icon
52
Tempest Therapeutics
TPST
$13.8M
– –
-384
Closed -$1.59M
TSRO
53
DELISTED
TESARO, Inc.
TSRO
– –
-195,092
Closed -$25.2M
KITE
54
DELISTED
Kite Pharma, Inc.
KITE
– –
-496,983
Closed -$89.4M
1 2
3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q4 2017 Portfolio in Review

As of Q4 2017, Avoro Capital Advisors held 55 positions worth $1.54B, up 20% from $1.29B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Avoro Capital Advisors deployed $211M of net new capital in Q4 2017, opening 12 new positions and adding to 18 existing holdings. Its largest new stake was TG Therapeutics: 3,294,463 shares worth $27M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 67% a quarter earlier.

On the sell side, the largest reduction was Pacira BioSciences, an estimated $18.3M trimmed.

  • Avoro Capital Advisors's largest Q4 2017 buy was TG Therapeutics: 3,294,463 shares worth $27M.
  • Avoro Capital Advisors added most to BioMarin Pharmaceuticals in Q4 2017, an estimated $51.4M increase.
  • Avoro Capital Advisors's biggest Q4 2017 reduction was Pacira BioSciences, cutting an estimated $18.3M.
  • Avoro Capital Advisors fully exited Kite Pharma, Inc. in Q4 2017, selling an estimated $89.4M.
  • Avoro Capital Advisors's ten largest holdings make up 63% of its $1.54B portfolio in Q4 2017.
  • Avoro Capital Advisors opened 12 new positions and closed 5 in Q4 2017.
  • Avoro Capital Advisors's portfolio value rose 20% quarter-over-quarter to $1.54B.

Based on Avoro Capital Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.